Question 1

What is the catalog number for 1-Bromo-2- (difluoromethyl) -3-methylbenzene?

Accepted Answer

The catalog number for 1-Bromo-2- (difluoromethyl) -3-methylbenzene is PC1005429.

Question 2

What sizes are available for 1-Bromo-2- (difluoromethyl) -3-methylbenzene?

Accepted Answer

1-Bromo-2- (difluoromethyl) -3-methylbenzene is available in the following size(s): 100 mg, 250 mg, 1 g.

Question 3

How many pack sizes does 1-Bromo-2- (difluoromethyl) -3-methylbenzene come in?

Accepted Answer

1-Bromo-2- (difluoromethyl) -3-methylbenzene is available in 3 different pack sizes.

Question 4

Is 1-Bromo-2- (difluoromethyl) -3-methylbenzene in stock?

Accepted Answer

1-Bromo-2- (difluoromethyl) -3-methylbenzene is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is the purity of this recombinant protein?

Accepted Answer

Purity, typically assessed by SDS-PAGE, is listed on the datasheet under quality control data.

Question 6

What do I do if this product arrives with reduced ice or a damaged cold-chain package?

Accepted Answer

Report this to us immediately with photos and your order reference. Our specialists will assess whether the product is still usable given the cold-chain interruption, and will arrange a replacement or credit if it isn’t.

Question 7

What host species was used to raise this antibody?

Accepted Answer

The host species used in production is listed under product specifications on the datasheet, and is relevant when selecting a compatible secondary antibody for your assay.

1-Bromo-2- (difluoromethyl) -3-methylbenzene

Product Specifications

CAS Number

MDL Number

Purity

Smiles

Available Sizes

Frequently Asked Questions

Explore Other Products

Human Transmembrane protein 30A (TMEM30A) activation kit by CRISPRa

FGD4 (N-term) Rabbit Polyclonal Antibody

trans-4-Hydroxy-L-proline

1-Ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)quinoline-3-carboxylic Acid Ethyl Ester

FITC Anti-Mouse IgD Antibody[11-26c.2a]

FITC Anti-Mouse IgD Antibody[11-26c.2a]